Hopewell, NJ, United States of America

Xiaolu Tao

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Xiaolu Tao

Introduction

Xiaolu Tao is an accomplished inventor based in Hopewell, NJ (US). He has made significant contributions to the field of medical research, particularly in the treatment of diseases related to Interferon gamma inducible protein 10 (IP-10). His innovative approach has led to the development of a unique method for administering anti-IP-10 antibodies.

Latest Patents

Xiaolu Tao holds a patent for his invention titled "IP-10 antibody dosage escalation regimens." This patent outlines a method for treating IP-10-related diseases by administering a predetermined dosage of an anti-IP-10 antibody. The process involves detecting the antibody levels in the subject and adjusting the dosage accordingly to ensure effective treatment. This innovative method has the potential to improve patient outcomes significantly.

Career Highlights

Xiaolu Tao is currently employed at Bristol-Myers Squibb Company, where he continues to advance his research in the field of immunology. His work focuses on developing therapies that target specific proteins involved in disease processes. With a patent portfolio that includes 1 patent, he has established himself as a key figure in his area of expertise.

Collaborations

Xiaolu has collaborated with notable colleagues, including Allison Y Luo and Wendy L Trigona. These partnerships have fostered a collaborative environment that enhances the research and development of innovative treatments.

Conclusion

Xiaolu Tao's contributions to the field of medical research exemplify the impact of innovation in healthcare. His patented methods for treating IP-10-related diseases highlight the importance of targeted therapies in improving patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…